Adipose-PRP Ovarian Rejuvenation
If you were told that you have no eggs or your eggs are bad quality, Adipose-PRP Ovarian Rejuvenation could help you have babies using your own eggs, and avoid Donor Eggs.
Advanced ovarian support using adipose-derived regenerative cells combined with PRP
Adipose-PRP ovarian rejuvenation is an advanced, research-driven fertility approach that combines platelet-rich plasma (PRP) with regenerative stem cells derived from a patient's own adipose (fat) tissue.
At Rejuvenating Fertility Center (RFC), this innovative option is offered to select patients seeking to optimize ovarian function—particularly women with very low ovarian reserve, poor response to conventional IVF, premature ovarian insufficiency (POI), or early menopause.
Why choose RFC for Adipose-PRP ovarian rejuvenation?
Rejuvenating Fertility Center is a global leader in ovarian rejuvenation:
-
The FIRST in the Northeast to pioneer PRP ovarian rejuvenation
-
The FIRST IN THE WORLD to offer Adipose-PRP ovarian rejuvenation
-
Leaders in treating women with diminished ovarian reserve (DOR)
-
Multiple peer-reviewed publications on PRP and Adipose-PRP ovarian rejuvenation
-
Care for patients nationwide and internationally
-
A philosophy focused on restoring function first and tailoring IVF only when appropriate
American Journal of Stem Cells, 2025;14(5)
RFC published the first documented live births in the world following intra-ovarian administration of adipose-derived stem cells combined with PRP in women aged 45 and older.
Publication: First live births after adipose-derived stem cells and platelet-rich plasma intraovarian administration
This report describes successful pregnancies in women over 45 using adipose-PRP ovarian rejuvenation following prior infertility and failed IVF attempts.
What is Adipose-PRP ovarian rejuvenation?
Adipose-PRP ovarian rejuvenation combines two autologous biologic components:
Platelet-Rich Plasma (PRP)
Derived from your blood
+
Adipose-derived regenerative cells
Obtained from a small fat sample
The goal is to support the ovarian environment using biologic signals that may help improve ovarian function and response in appropriately selected patients. This approach is often considered when a patient desires a more intensive regenerative strategy than PRP alone.
This treatment is not about adding eggs. Instead, it is designed to support ovarian function and responsiveness—how each patient responds can vary significantly.
Why adipose (fat)?
RFC uses adipose tissue because it is:
-
Easily accessible through a small, minimally invasive mini-liposuction
-
A well-studied source of regenerative cells in human medicine
-
Autologous (from the patient's own body), reducing immunogenic risk
Adipose-containing regenerative stem cells are combined with PRP to create a biologic environment intended to support ovarian function.
How the Adipose-PRP procedure is performed
PRP preparation (≈40 minutes)
Blood is drawn from the arm and processed to prepare platelet-rich plasma.
Mini liposuction (≈30 minutes)
A small amount of fat is gently collected from the abdomen through a tiny entry point (usually <1 cm). Regenerative cells are extracted from the adipose tissue.
Combination + delivery (≈20 minutes)
The adipose-derived regenerative component is combined with PRP and injected intra-ovarianly under ultrasound guidance (and in select cases, intra-uterine), with anesthesia and comfort measures provided.
Most patients spend approximately 2 hours at the clinic.
What happens after Adipose-PRP?
After the procedure, patients typically undergo weekly monitoring for 2–8 weeks, including:
-
Hormone testing
-
Vaginal ultrasound with follicle tracking
-
It might take few months in certain cases to see any improvement
If ovarian response improves, your physician may recommend timing fertility treatment, such as IVF, based on individualized findings.
Who may benefit from Adipose-PRP ovarian rejuvenation?
1. Very low AMH or diminished ovarian reserve (DOR)
Have very low AMH or diminished ovarian reserve (DOR) and wish to pursue pregnancy using their own eggs
2. Poor ovarian response
Have had a poor ovarian response to prior IVF cycles
3. Egg or embryo quality concerns
Have concerns regarding egg or embryo quality
4. Premature ovarian insufficiency (POI)
Have premature ovarian insufficiency (POI) or early menopause (careful case selection required)
5. Structured, monitored plan
Want a structured, closely monitored plan guided by an experienced, research-focused fertility team
OVARIAN REJUVENATION SUCCESS RATES AND RESEARCH FROM RFC:
-
Zaher Merhi. Clinical practice perspectives on adipose-derived stem cells and platelet-rich plasma for female infertility treatments. Future Sci OA. 2025 Dec;11(1):2580233.
-
Zaher Merhi, Bhavika Garg, Jessica Haroun. Endocrine and regenerative mechanisms of adipose-derived stem cells in female infertility. Front Endocrinol (Lausanne). 2025 Oct 21:16:1694025
-
Zaher Merhi and Marco Mouanness. Intraovarian platelet-rich plasma administration could improve blastocyst euploidy rates in women undergoing in vitro fertilization. Clin Exp Reprod Med. 2022;49:210-214.
- Zaher Merhi and Marco Mouanness. Intraovarian Platelet-Rich Plasma administration Induced Spontaneous Ovulation in an Anovulatory Woman with PCOS. JCEM Case Reports. 2023;21;1:38.
-
Zaher Merhi and Marco Mouanness. Intraovarian PRP Injection Improved Hot Flashes in a Woman With Very Low Ovarian Reserve. Reprod Sci. 2022;29:614-619.
-
Marco Mouanness and Zaher Merhi and. Use of Intra-uterine Injection of Platelet-rich Plasma (PRP) for Endometrial Receptivity and Thickness: a Literature Review of the Mechanisms of Action. Reprod Sci. 2021;28:1659-1670.
-
Zaher Merhi and Marco Mouanness. Ovarian response to intraovarian platelet-rich plasma (PRP) administration: hypotheses and potential mechanisms of action. J Assist Reprod Genet. 2022;39:37-61.
-
Zaher Merhi, Catrina Wiltshire McLeod, Fawziyah Shamim. Platelet-Rich Plasma in Reproductive Endocrinology: Mechanisms and Clinical Applications for Ovarian Reserve, PCOS, and Endometrial Receptivity. Biomedicines. 2025 Oct 13;13(10):2488.